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ABSTRACT  
Epidemiological evidence supports a positive relationship between fruit and vegetable (FV) 
intake, lung function and chronic obstructive pulmonary disease (COPD). Increasing FV 
intake may attenuate the oxidative stress and inflammation associated with COPD.  
 
An exploratory randomised controlled trial to examine the effect of increased consumption of 
FV on oxidative stress and inflammation in moderate to severe COPD was conducted. Eighty-
one symptomatically stable patients with a habitually low FV intake (≤2 portions FV/day) 
were randomised to the intervention group (≥5 portions FV/day) or the control group (≤2 
portions FV/day). Each participant received self-selected weekly home deliveries of FV for 12 
weeks.  
 
Seventy-five participants completed the intervention. There was a significant between-group 
change in self-reported FV intake and biomarkers of FV intake (zeaxanthin, P=0.034 and -
cyptoxanthin, P=0.015) indicating good compliance; post-intervention intakes in intervention 
and control groups were 6.1 and 1.9 portions FV/day respectively. There were no significant 
changes in biomarkers of airway inflammation (interleukin-8, myeloperoxidase) and systemic 
inflammation (C-reactive protein) or airway and systemic oxidative stress (8-isoprostane). 
 
This exploratory study demonstrated that patients with moderate to severe COPD were able to 
comply with an intervention to increase FV intake, however, this had no significant effect on 
airway or systemic oxidative stress and inflammation.  
 
KEYWORDS: Chronic obstructive pulmonary disease, fruit, inflammation, oxidative 
stress, vegetables 
 
Word count: 2950 
 
Trial registration number: NCT00435708; www.clinicaltrials.gov  
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INTRODUCTION 
The World Health Organisation (WHO) have predicted that, between 1990 and 2020, COPD 
will move from the sixth- to the third-leading cause of death worldwide [1]. Systemic and 
airway inflammation and increased levels of oxidative stress are key pathophysiological 
features of COPD. Thus, factors that can ameliorate these underlying inflammatory processes 
and/or help to redress the oxidant/antioxidant balance are of therapeutic interest. 
 
A number of dietary constituents possess anti-inflammatory and antioxidant properties and, 
hence, are of interest with respect to the pathogenesis of COPD. Many cross-sectional studies 
have demonstrated a significant positive association between fruit and vegetable (FV) intake 
and forced expiratory volume in one second (FEV1), with evidence particularly strong for fruit 
[2-3] but also evident for vegetables [4-5]. Other research has indicated an inverse association 
between FV intake and COPD symptoms [2, 4] and Carey et al. [6] demonstrated that a lower 
fruit intake was associated with a decline in FEV1 over 5-7 years follow-up. Furthermore, fruit 
intake has also been inversely associated with 20-25 year incidence of chronic non-specific 
lung disease and COPD mortality [2, 7]. A recent systematic review on vitamins and COPD, 
found that the intake of many vitamins commonly found in fruits and vegetables, are 
associated with features of COPD and highlighted the need for prospective randomised 
controlled trials in this field [8]. 
 
It is possible that dietary interventions may attenuate the oxidative stress and inflammation 
associated with COPD, which may, in turn, translate into beneficial outcomes for patients. 
Few food-based interventions in COPD have been published to date [9-10]. Cerdá et al. [9] 
randomised 30 stable COPD patients to consume 400ml of pomegranate juice or 400ml of a 
synthetic orange-flavoured drink daily for five weeks. They found no significant differences 
between the groups in lung function or clinical symptoms of COPD. Although juice was 
provided to participants on a weekly basis, nutritional biomarker compliance data was not 
reported. To date, there has only been one broad FV intervention in COPD patients. Keranis et 
al. [10] reported that a dietary shift from low to modest consumption of FV (based on 
patients’ self-reported intake, objective biomarkers of FV intake were not reported) was 
associated with an increase in FEV1 in a 3-year randomised prospective study in COPD 
patients. Participants were randomised to receive either advice at 6-monthly intervals to 
increase FV intake (n=60) or to freely choose their own diet (n=60). 
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Given the epidemiological evidence to date, there is a need to further explore the relationship 
between FV intake and COPD in randomised controlled trials (RCTs). The aim of this study 
was to conduct an exploratory RCT to examine the effect of increased consumption of FV on 
oxidative stress and inflammation in people with moderate to severe COPD. The study design 
incorporated strategies to maximise adherence to the intervention and assessed objective 
biomarkers of compliance.  
 
METHODS 
Ethics and participants 
Ethical approval was received from The Office for Research Ethics Committees Northern 
Ireland (ORECNI). All volunteers gave written informed consent. Participants were recruited 
between February 2007 and February 2009 from respiratory outpatient clinics at four Belfast 
hospitals. Inclusion criteria were: symptomatically stable, moderate to severe COPD (FEV1 
<80%) and a habitually low FV intake (≤2 portions FV/day; assessed by diet history, see 
below). Exclusion criteria included a history of diabetes mellitus, a regular intake of high dose 
antioxidant vitamin supplements and an arterial oxygen tension (PaO2) <8kPa.  
 
Study design  
This was a 12-week open-label randomised controlled intervention study. A 12-week period 
was chosen for this intervention study as this has been shown to be sufficient time to ensure 
an increase in micronutrient status [11] in response to FV interventions, and also to induce 
changes in plasma C-reactive protein (CRP) and urinary isoprostanes [12-13]. IL-8 has 
recently been shown to be responsive to 10-week dietary interventions (with bread [14] and 
cheese [15]). After obtaining consent, participants were randomly assigned, in blocks of four 
using a random-number generator (www.randomization.com), to the intervention group (≥5 
portions FV/day) or the control group (≤2 portions FV/day). A portion was as defined by the 
Food Standards Agency, i.e. an 80g serving of FV or 150ml fruit juice. During the 12-week 
intervention, each participant received self-selected weekly home deliveries of FV from a 
local retailer. Participants were advised on suitable storage and cooking methods and how best 
to incorporate the FV into their diet. Participants were also contacted weekly by the study 
researcher (FB) to encourage compliance, record self-reported exacerbations and to discuss 
any difficulties they were experiencing. Throughout the intervention, participants were 
advised to maintain their usual level of physical activity and keep other lifestyle factors 
unchanged.  
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Study assessments 
Participants attended the Regional Respiratory Centre, Belfast City Hospital, for study 
assessments at baseline (week 0) and post-intervention (week 12). The same assessments were 
performed at each visit. A questionnaire was administered to assess alcohol intake and 
smoking status. Anthropometric measurements (weight, height, waist and hip circumference) 
were taken with participants in light indoor clothing and without shoes using standard 
protocols. A non-fasting blood sample (participants were advised to consume a standard 
breakfast of tea and toast at home before attending for study assessments), a spot urine sample 
and an induced sputum sample (see below) were collected. All biological samples were 
processed and frozen at –80ºC within 2 hours of collection. Blood pressure was recorded 
using a WelchAllyn automated sphygmomanometer (Nimed Ltd, Belfast) on the right arm in a 
seated position after resting for 10-15 minutes. The average of three readings was recorded. A 
pulmonary function test, without the use of a bronchodilator, was carried out to assess FEV1 
and forced vital capacity (FVC) according to the American Thoracic Society/European 
Respiratory Society Task Force recommendations [16]. Knudson 83 predicted references were 
used to calculate lung functions [17]. A series of 7-day diet histories were completed by each 
participant at weeks 0, 6 and 12 in order to assess baseline diet and self-reported compliance 
with the intervention; average daily FV intake was then hand-counted from these records. 
 
Sputum induction and processing 
4ml of a 4.5% saline solution was nebulised using an EASYneb II nebuliser (Nebuliser Flaem 
Nuova S.p.A., Italy, 2002) by the participant. After 5 minutes, participants were encouraged 
to cough and clear a sample. This procedure was repeated until the saline was finished 
(approximately 15-20 min). Sputum was processed and treated according to the method of 
Kelly et al. [18].  
 
Laboratory analysis 
All laboratory analysis was performed on a blinded basis. Plasma ascorbic acid concentrations 
were measured on a Cobas FARA centrifugal analyser with a fluorescent attachment [19]. 
Serum concentrations of lutein, zeaxanthin, -cryptoxanthin, α-carotene, -carotene and 
lycopene were determined by reverse-phase high-performance liquid chromatography (HPLC) 
with diode array detection [20]. Assays were standardised against appropriate National 
Institute of Standards and Technology (NIST) reference materials. Sputum myeloperoxidase 
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(MPO), interleukin-8 (IL-8) and serum cotinine were analysed by ELISAs on a Triturus® EIA 
Analyser system (Grifols S.A. Barcelona, Spain). Plasma CRP was measured with standard 
enzymatic assays (Randox, Crumlin, Northern Ireland) on an automated ILab-600 
biochemical analyser (Instrumentation Laboratories, United Kingdom). Sputum neutrophil 
elastase was measured using an in-house continuous activity assay [21]. Sputum and urinary 
8-isoprostanes were measured using an AutoDelfia (Dissociation Enhanced Lanthanide Fluoro 
ImmunoAssay) assay [22].  
 
Statistical methods 
All statistical analyses were carried out using Statistical Package for the Social Sciences 
(SPSS) for Windows version 17.0 (SPSS Inc, Chicago, IL). Results are expressed as mean ± 
SD for normally distributed continuous variables. Skewed variables were logarithmically 
transformed for parametric analysis and presented as geometric mean and interquartile range. 
An independent samples t-test was used to compare the two groups at baseline and to examine 
differences in mean change between groups. Within group changes in endpoints were assessed 
using paired samples t-tests. Analysis was performed on the intention-to-treat principle; six 
participants (four in the control group and two in the intervention group) dropped out of the 
study (reasons given in results section below) and did not attend for the week 12 assessments 
so could not be included in an intention-to-treat analysis. The Chi-Square test was used to 
examine differences in nominal or categorical variables between groups. 
 
A secondary analysis was also conducted removing data for participants who had experienced 
an exacerbation close to completion of the study as this may have had an acute effect on the 
outcome measures, thus masking the chronic effects of the intervention.  Participants were 
excluded from this analysis if they had an elevated CRP level (>20 mg/L) at the end of the 
study as well as a self-reported exacerbation within the two weeks [23] prior to the study end. 
For the purposes of this study, we defined an exacerbation as “a sustained worsening of 
respiratory symptoms that is acute in onset and usually requires a patient to seek medical help 
or alter treatment [24].”  
 
RESULTS 
Summary of participant recruitment (Figure 1) 
In total, 454 patients from four hospitals in Belfast were eligible to take part in this study; 373 
(82.2%) declined. Reasons for declining participation included being unwilling to give up 
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time or to travel for study assessments (27.6%), a dislike of giving blood samples (4%), 
discouragement from other family members (8%), feeling too unwell (47%), and being 
uninterested in research (13.4%). 
 
A total of 81 participants completed the baseline assessments and 75 participants completed 
the intervention. There were six dropouts in total following randomisation: four from the 
control group (one due to back injury, two who were admitted to hospital with other medical 
complications and one individual was unable to continue to participate owing to personal 
reasons) and two from the intervention group (one suffered a cardiovascular event and one 
died due to another medical complication). The intervention was implemented as intended and 
there were no adverse events associated with the intervention. The availability of paired data 
is indicated in the tables; it varies for the individual endpoints studied according to successful 
collection of biological material. 
 
Baseline characteristics 
Participants included 46 males (57%) and 35 females (43%). Forty-one percent of participants 
(n=33) had moderate COPD (FEV1 <80% predicted) and 59% (n=48) had severe COPD 
(FEV1 <50% predicted). Two (2.5%) participants were underweight, n=31 (38.3%) were 
normal weight, n=20 (24.7%) were overweight and n=28 (34.5%) were obese according to 
WHO criteria for body mass index. Seventy-five percent suffered from comorbidities. There 
were no significant differences in baseline characteristics between the two randomised groups 
(Table 1). Overall, 94% of the sample had low serum α-carotene status and 93% had low 
serum β-carotene status using cut-offs defined by Gey (1998) as being indicative of increased 
risk of cardiovascular disease and cancer [25]. There was evidence of biochemical depletion 
of vitamin C (status <11 µmol/L) in 21% of the sample (data not shown). There was no 
significant difference at baseline in inflammatory or oxidative stress biomarkers in 
participants with moderate versus severe COPD (data not shown). 
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TABLE 1 
General baseline characteristics1 of 81 participants with moderate to severe COPD according 
to randomisation to a low or high FV group 
Variable 
Low FV group 
(n=41max) 
High FV group 
(n=40max) 
Age (y) 61.2 ± 8.3 63.2 ± 9.1 
Men 25 (61%) 21 (53%) 
Height (m) 1.66 ± 0.10 1.66 ± 0.10 
Weight (kg) 74.3 ± 15.5 77.3 ± 16.7 
BMI (kg/m2) 27.2 ± 5.7 28.2 ± 6.0 
Systolic blood pressure (mmHg) 134.7 ± 20.1 139.6 ± 19.5 
Diastolic blood pressure (mmHg) 78.7 ± 8.8 81.1 ± 9.7 
Current smokers 22 (54%) 14 (35%) 
Former smokers 18 (44%) 26 (65%) 
Number of pack years 34.4 (20.9-59.9) 40.5 (19.9-60.0) 
Education (years) 10.7 ± 2.1 11.3 ± 2.2 
FEV1 (% predicted): 50.4 ± 17.6 45.2 ± 17.0 
- Moderate COPD: n (FEV1range) 19 (52-85%) 14 (51-88%) 
- Severe COPD: n (FEV1 range) 22 (20-49%) 26 (20-50%) 
FVC (% predicted) 77.4 ± 20.9 73.9 ± 16.7 
FEV1/FVC (% predicted) 65.6 ± 16.8 60.4 ± 15.7 
FV intake (portions/day) 1.4 ± 0.6 1.5 ± 0.7 
1Continuous variables are summarised as mean ± SD for normally distributed data and 
geometric mean (interquartile range) for skewed data. FV: fruit and vegetables; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; FEV1/FVC: forced expiratory 
volume in one second to forced vital capacity ratio. 
          
Change in self-reported FV intake (Figure 2) 
At the study end, there was a significant between-group difference (P<0.001) in change in 
self-reported FV intake as a result of the intervention; the intervention group increased intake 
by 4.6 portions per day (from 1.5±0.7 portions/day to 6.1±1.8 portions/day). The control 
group also had a marginal increase in FV intake of 0.5 portions per day (from 1.4±0.6 
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portions/day to 1.9±0.5 portions/day), but were still consuming the target intake for this group 
of <2 portions FV/day at the end of the intervention.   
 
Change in biomarkers of FV intake  
Table 2 reports the change in micronutrient status according to study group. There was a 
significant between-group difference in change in zeaxanthin (P=0.034) and β-cryptoxanthin 
(P=0.015) status at 12 weeks. There was also a trend for a between-group difference in change 
in lutein status (P=0.076). 
 
At baseline 92.5% of the sample had low serum α-carotene status and low serum β-carotene 
status using cut-offs defined by Gey (1998) as being indicative of increased risk of 
cardiovascular disease and cancer [25]. At the end of the intervention period, 79% had low 
serum α-carotene status and 84% had low serum β-carotene status. Likewise, for vitamin C, 
12.5% of the intervention group had evidence of biochemical depletion of vitamin C (status 
<11 µmol/L) at baseline compared to 0% at the end of the intervention. 
 
Change in other lifestyle factors 
There was no significant change in alcohol intake, smoking status or serum cotinine 
concentrations during the intervention for participants in either the intervention or control 
group (data not shown). 
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TABLE 2 
Changes in biochemical markers of micronutrient status according to FV allocation in moderate to severe COPD patients 
Variable         
(μmol/L) 
Low FV diet  
(n=36) 
 
High FV diet  
(n=38) Between-group 
comparison P 
value3 Week 01 Week 12 
% 
change 
Within 
group P 
value2   
Week 0 Week 12  
% 
change 
Within 
group P 
value2 
Vitamin C  30.664 ± 26.9754 33.439 ± 21.193 9 0.344  35.676 ± 19.953 47.642 ± 19.231 34 0.001 0.040 
Lutein  0.145 (0.100-0.228)5 0.158 (0.122-0.218) 9 0.046  0.154 (0.117-0.208) 0.187 (0.140-0.247) 21 <0.001 0.076 
Zeaxanthin 0.026 (0.021-0.033) 0.028 (0.020-0.042) 8 0.152  0.023 (0.017-0.031) 0.029 (0.021-0.041) 26 <0.001 0.034 
-cryptoxanthin  0.033 (0.023-0.048) 0.043 (0.027-0.061) 30 0.004  0.041 (0.029-0.057) 0.067 (0.039-0.108) 63 <0.001 0.015 
α-carotene  0.040 (0.032-0.069) 0.048 (0.031-0.085) 20 0.019  0.048 (0.037-0.066) 0.064 (0.046-0.093) 33 0.001 0.431 
-carotene  0.148 (0.100-0.256) 0.179 (0.126-0.310) 21 0.016  0.191 (0.136-0.273) 0.229 (0.160-0.288) 20 0.003 0.948 
Lycopene  0.250 (0.165-0.415) 0.301 (0.189-0.515) 20 0.217   0.212 (0.137-0.432) 0.266 (0.166-0.541) 25 0.185 0.489 
1 Baseline values (before diet) did not differ significantly between-groups (independent samples t-test). 2 Within-group comparisons analysed by paired samples t-test. 
3Analysed by independent samples t-test. 4 Values are mean ± SD. 5 Values are geometric mean (interquartile range). FV: fruit and vegetables.
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Change in lung function, oxidative stress and inflammation 
There were no significant differences between the low versus high FV group for lung function 
tests or for any of the biomarkers of oxidative stress and inflammation (Table 3).  
 
Exacerbations during the intervention 
During the 12-week study, 15 participants in the control group had an exacerbation (of which 
3 required hospitalisation) and 20 participants in the intervention group had an exacerbation 
(of which 3 required hospitalisation); exacerbation rate did not differ significantly between 
groups (Chi-square statistic: P=0.223). In total, 16 participants had a CRP level greater than 
20 mg/L at week 12 and had experienced an exacerbation within the 14 days prior to the end 
of the study. When the analysis was conducted following removal of these 16 participants, 
again, there were no significant differences between the two groups for any of the 
inflammatory or oxidative stress markers measured (data not shown). 
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TABLE 3  
Change in markers of lung function and biomarkers of oxidative stress and inflammation according to FV allocation in moderate to severe COPD 
patients 
Variable 
Low FV diet (n=37max)  High FV diet (n=38max) Between-
group 
comparison 
P value3 
Week 01 Week 12 % change 
P 
value2  Week 0 Week 12 
% 
change 
P 
value2 
FEV1 (% predicted),             
(nL=37, nH=38) 
50.3 ± 18.54 51.8 ± 17.7 3 0.288  45.1 ± 17.3 45.8 ± 17.5 2 0.552 0.654 
FVC (% predicted),          
(nL=37, nH=38) 
77.2 ± 21.9 83.8 ± 19.8 9 0.032  74.3 ± 16.8 75.8 ± 17.1 2 0.356 0.142 
FEV1/FVC (% predicted), 
(nL=37, nH=38) 
65.6 ± 17.5 62.1 ± 16.1 -5 0.103  60.1 ± 16.0 59.1 ± 15.8 -2 0.484 0.306 
IL-8 - sputum (ng/mL),  
(nL=20, nH=21) 
9.00 (4.75-20.49) 7.67 (4.43-15.88) -15 0.538  11.68 (5.42-19.20) 9.99 (4.53-15.92) -15 0.407 0.992 
MPO - sputum (ng/mL), 
(nL=29, nH=29) 
956 (498-1891) 947 (493-2084) -1 0.945  1218 (590-2330) 1384 (836-1881) 14 0.427 0.500 
NE - sputum (µg/mL),    
(nL=16, nH=20) 
4.93 (0.18-17.20) 2.92 (0.68-4.61) -41 0.348  2.94 (0.77-11.16) 2.33 (0.64-7.72) -21 0.453 0.621 
CRP - plasma (mg/L),  
(nL=36, nH=38) 
4.15 (1.75-8.52) 3.39 (1.89-6.21) -18 0.309  3.38 (1.63-6.26) 4.09 (1.98-5.99) 21 0.219 0.116 
8-iso - urine (nM/mM 
creatinine), (nL=34, nH=35) 
1.54 (1.08-1.90) 1.41 (1.04-1.74) -8 0.104  1.76 (1.17-2.07) 1.65 (1.21-2.27) -6 0.353 0.806 
8-iso - sputum (ng/mL),  
(nL=27, nH=25) 
1.84 (1.17-3.28) 1.70 (1.26-2.42) -8 0.743  1.44 (0.9-3.04) 1.83 (1.18-2.63) 27 0.302 0.334 
1 Baseline values (before diet) did not differ significantly between-groups (independent samples t-test). 2 Within-group comparisons analysed by paired samples t-test.  
3Analysed by independent samples t-test. 4 Continuous variables are summarised as mean ± SD for normally distributed data and geometric mean (interquartile range) for 
skewed data. nL = number of participants in low FV diet. nH = number of participants in high FV diet. FV: fruit and vegetables; FEV1: forced expiratory volume in one second; 
FVC: forced vital capacity; FEV1/FVC: forced expiratory volume in one second to forced vital capacity; IL-8: interleukin 8; MPO: myeloperoxidase; NE: neutrophil elastase; 
CRP: C-reactive protein; 8-iso: 8-isoprostane.
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DISCUSSION 
The health benefits of FV are well supported by observational epidemiology but it is only 
recently that data regarding the precise nature of their biological effects has started to emerge 
from randomised controlled trials [26]. Examination of these effects in both healthy and 
diseased groups will help to inform both public health messages and evidence-based clinical 
practice. This trial is the first to explore the effect of increased FV intake on biomarkers of 
inflammation and oxidative stress in patients with moderate to severe COPD. Participant 
retention rates were high and both self-reported FV intake and biomarkers of FV intake 
indicated that the intervention was implemented successfully in this group of patients; with 
the high FV group consuming a mean of six portions of FV per day by the end of the 
intervention from a baseline of less than two portions a day. Despite evidence of good 
compliance with the study protocol, there was, however, no significant difference between the 
two groups for markers of oxidative stress or inflammation. 
 
The biomarkers chosen for this study, in particular IL-8 which has been most extensively 
studied, are reliable indicators of airway inflammation and oxidative stress in COPD 
populations [27-28]. IL-8 and systemic CRP correlate positively with disease severity, 
exacerbation rates and lung function decline in COPD [28]; the lack of a significant difference 
in disease biomarkers according to disease severity in this study is most likely owing to the 
large inter-individual variability that was encountered. Recently, food-based interventions 
with bread (n=20) and cheese (n=10) [14-15] for ten weeks in generally healthy participants 
have induced significant lowering of circulating IL-8 concentrations. CRP and isoprostanes 
are well regarded as biomarkers of inflammation and oxidative stress, respectively [29-30]. 
Cross-sectional studies generally support an association between higher FV intake and lower 
serum levels of CRP, however FV interventions in healthy populations have shown mixed 
results [31]. Watzl et al. [12] demonstrated a significant reduction in plasma CRP following 
4-weeks on a high FV diet in healthy non-smoking men and a 2-year Mediterranean-style 
dietary intervention in patients with metabolic syndrome significantly lowered serum levels of 
CRP, IL-6, IL-7 and IL-18 [32]. Thompson et al. [13] reported a reduction in the excretion of 
8-isoprostanes after an 8-week high FV diet in healthy women. However, two recent 
intervention studies, a 2-month Mediterranean diet intervention [33] and a 2-month FV 
intervention [26] have shown no effect of increased FV intake on circulating CRP, yet these 
studies have been able to demonstrate significant improvements in measures of vascular 
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function (flow-mediated dilatation and venous occlusion plethysmography, respectively), thus 
indicating that such biomarkers may be dissociated from true biological effects and, therefore 
may be of limited use in dietary studies [31]. Further novel biomarkers of COPD may prove to 
be more sensitive to FV or antioxidant interventions and assessment of a broader panel of 
biomarkers may be prudent in such work, however, costs often prohibit such explorations.  
 
The assessment of airway inflammation and oxidative stress was limited, to some extent, by 
the success rate of induced sputum collection as paired samples were obtained for 77% of the 
sample; this should be considered when planning future similar studies. The large intra- and 
inter-study variability and lack of data on within-subject variability in inflammatory markers 
in COPD [34] makes it difficult to estimate the sample size for a definitive study; a 
retrospective power calculation based on the numbers of subjects actually included in the final 
analysis showed that, assuming no change in end-points in our control group, the study had in 
excess of 80% power to detect a 60% reduction on IL-8, a 45% reduction in MPO and a 50% 
reduction in plasma CRP in the intervention group. To give an indication of sample sizes 
required to detect smaller changes, based on the variability of changes in log-transformed IL-8 
values observed in our data, a study of 400 COPD subjects (n=200/group) would be required 
to detect a 25% change in IL-8 values on intervention with 80% power.  A larger sample size 
would, of course, have improved the power of the study; however, even trends towards 
significance were not apparent in the data. 
 
Although circulating antioxidant status increased in this study it cannot be assumed that this, 
in turn, impacted on airway antioxidant status.  Little is still known about how the antioxidant 
pool in the respiratory tract lining fluid is maintained and whether or not dietary antioxidant 
intake can influence this process [35]. A study in non-asthmatic children reported a significant 
correlation between ascorbate in bronchoalveolar lavage and ascorbate concentrations in 
serum (r=0.297, P=0.018) [36], indicating that dietary antioxidants may be able to influence 
antioxidant defences in the lung. An investigation of antioxidant levels in induced sputum 
samples from this study would help to elucidate the relationship between dietary antioxidant 
intake and antioxidant concentrations within the respiratory tract.  
 
To our knowledge, there is only one other FV intervention in COPD patients to date. Keranis 
et al. [10] recently reported findings from a 3-year prospective study in which participants 
from COPD outpatient clinics in Greece, were randomised to consume a diet with increased 
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consumption of fresh FV (n=60) or to consume a diet of their own free choice (n=60). The 
intervention group were given advice to consume FV which was reinforced every 6 months at 
scheduled outpatient appointments. The study reported that the intervention group, who 
changed their diet from low to modest consumption of FV (change in terms of portions for 
fruit and vegetables not reported), displayed an increase in FEV1, whereas control group 
patients exhibited a decline in lung function (P=0.03 for difference between groups). The lack 
of objective compliance data in this long-term study makes it difficult to confidently attribute 
the positive observations to increased consumption of FV. This study did, however, employ a 
long-term follow-up of participants and, it is possible that, given the chronic nature of COPD, 
such a lengthy follow-up may be necessary in order to examine the true biological effects of 
dietary interventions in this population. It is also encouraging that the patient group studied by 
Keranis et al. [10], approximately 78% of whom had moderate to severe COPD, were able to 
increase FV intake and sustain this for 3 years, however the caveat regarding objective 
biomarkers of FV intake discussed above remains a limiting issue.    
 
In the present study there was a significant change in FV intake between the intervention and 
control group (difference in change in FV intake was 4.2 portions/day between the groups), 
and this was reflected in significant between-group differences in biomarkers of FV intake 
(zeaxanthin and β-cryptoxanthin). The control group did increase their intake of FV by, on 
average, 0.5 portions per day but their overall mean intake remained within the study target of  
<2 portions per day. This increase in intake in the control group was minimal and not 
unexpected given the fact that the intervention involved home delivery of FV to both groups, 
as well as weekly contact with the study researcher, both of which would heighten awareness 
of consumption. 
 
The limitations of the present study must be acknowledged. This was, by necessity, an open-
label study, however the laboratory analysis was performed on a blinded basis. It was also a 
short-term intervention and so results cannot be extrapolated to the situation of chronic 
consumption. Furthermore, two barriers (cost and access) to FV intake were removed in the 
study in order to enhance compliance. Participants were asked not to make any other lifestyle 
changes during the study and they reported no change in smoking behaviour or alcohol intake. 
However, physical activity was not assessed pre- and post-intervention. Whilst changes in 
physical activity may be unlikely in this population, it cannot be ruled out as a potential 
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confounder. Exacerbation assessment is also a limiting factor. Although exacerbation rate did 
not appear to differ between groups, it is important to note that exacerbations were self-
reported and were not verified by medical records. Finally, the participants in this study may 
not be representative of all patients with moderate to severe COPD, 82% of eligible 
participants declined to participate and patients with lower BMI’s were under-represented; it 
is likely that such individuals declined to participate owing to the perceived demands of the 
study.  
 
Further work in this area should not be precluded based on the results of this initial study 
alone as many individual factors could affect the outcome of such work. Dietary interventions, 
such as this, may have differing effects in different sub-groups of COPD patients. The study 
duration and endpoints that are most likely to be responsive are also a critical consideration; it 
is possible that longer-term dietary interventions may be more effective in COPD. In terms of 
the nature of the intervention itself, there are many possible approaches, each with their own 
merits, for example, one could hypothesise that a broader dietary approach that focuses on 
several key foods or food groups, rather than focusing on one particular food group (FV) may 
be more likely to have a beneficial effect.  
 
In conclusion, this study demonstrated that patients with moderate to severe COPD were able 
to comply with an intervention to increase FV intake; however, this increased intake had no 
significant effect on airway or systemic oxidative stress and inflammation. Although no signal 
was apparent, a potentially beneficial effect of increased FV intake in COPD cannot be 
excluded based on this exploratory study alone as longer-term interventions, with different 
endpoints, may be required to demonstrate biological effects in this population. The 
experiences from this trial in terms of feasibility of recruitment, challenges of induced sputum 
sample collection and variance in the study endpoints should be considered when planning 
future studies in this area.  
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